Purpose: BRCA1-related breast cancers are more frequently estrogen receptor (ER) negative than are either BRCA2-related or nonhereditary breast cancers. The relationship between ER status and other clinical features of hereditary breast cancers has not been well studied.
INTRODUCTION
It has been recognized for several years that BRCA1-related breast cancers are more likely to be estrogen receptor (ER) negative than are non-BRCA1-related breast cancer and BRCA2-related breast cancers (1, 2) . Tamoxifen appears to be effective in reducing both local recurrence and contralateral breast cancer among women with BRCA1 mutations (3). These two observations appear to stand in contradiction to each other because in general, hormone-based treatments such as tamoxifen are not effective in preventing or treating ER-negative breast cancer (4, 5) . The widely voiced opinion that tamoxifen is likely to be ineffective in preventing BRCA1-related breast cancers is mainly based on an analysis of the NSABP-P1 (prevention) trial of tamoxifen versus placebo. Among 8 BRCA1 mutation carriers (hereafter BRCA1 carriers) who developed breast cancer, 5 had been allocated to tamoxifen and 3 had been allocated to placebo (6) . The estimated risk ratio was 1.67 [95% confidence interval (CI) 0.32-10.70], which favors no protective effect of tamoxifen. The study design is ideal (prospective and randomized), but the number of BRCA1 carriers was small (n ϭ 8). In contrast, a large case-control study of BRCA1 carriers with and without contralateral breast cancer suggested that tamoxifen is a highly effective method of preventing second primary breast cancers in BRCA1 carriers (7) . The adjusted odds ratio for contralateral breast cancer in association with tamoxifen use among BRCA1 carriers was 0.38 (95% CI 0.19 -0.74). By inference, the authors concluded that tamoxifen would likely also be effective in preventing primary breast cancer in BRCA1 carriers. This interpretation fits with the results of a study of prophylactic oophorectomy in BRCA1 carriers, where removal of the ovaries, and the resulting estrogen deprivation, resulted in highly significant 47% reduction in the risk of breast cancer (8) . Given all of the data, the most parsimonious explanation of these conflicting data are that the NSABP-P1 study was underpowered to detect a protective effect of tamoxifen in BRCA1/2 carriers. However, an alternative hypothesis is that the ER status of the two tumors is highly correlated. In this scenario, if the first cancer is ER positive, then the contralateral tumor is also likely to be ER positive. Thus, tamoxifen treatment of the ER-positive first cancer would be effective in preventing the second cancer because of its predicted ER-positive status. Finally, it is possible that menopause results in a significant increase in the proportion of BRCA1-related cancers that are ER positive, favoring successful prevention of the second breast cancer by tamoxifen in postmenopausal women. The casecontrol study (7) did not contain sufficient information regarding the ER status of either the first or the second cancer to eliminate the possibility that the observed effect was due to prevention of second cancers that were destined to be ERpositive (9) .
We have recently shown that tamoxifen is effective at reducing both local recurrence and contralateral breast cancer among women with BRCA1 mutations (3). However, in that study, much of the ER data were missing. One possible way to circumvent the missing ER data are to identify other features of the breast cancer that predict ER status and then use these tumor characteristics as surrogate markers of ER status. In a small series of cases from Montreal, Quebec, Canada, we observed that 16 of 18 (89%) grade 3, infiltrating ductal breast cancers, which occurred among BRCA1 carriers, were ER negative. Here, we attempted to confirm this initial observation in an expanded series of cases. We also wished to establish whether BRCA1-related breast cancer is more likely to be ER negative than non-BRCA1-related breast cancer, even after adjusting for the effects of age, grade, and histological type.
MATERIALS AND METHODS
Subjects Included in Study. Three different sets of breast cancer patients were included in this study. The first set consists of a historical cohort of 276 Ashkenazi Jewish women who were diagnosed with a first primary invasive breast cancer, at Ͻ65 years of age, at a single Montreal institution between January 1980 and November 1995. They were all tested for the three founder mutations in BRCA1/2 that are common in the Ashkenazi Jewish population. The histological type, grade and ER status were determined by one pathologist (L. R. B.). ER status was determined by immunohistochemistry, and tumors were deemed positive if Ն10% of the total number of tumor cells examined showed clear and intense staining with the anti-ER antibody used, with no background cytoplasmic staining, as described previously (1) . The ascertainment criteria and mutation analysis performed for these women have been described elsewhere (10, 11) . Tumors Ն 51 mm were excluded, so as to match the second series (see below). Among the 246 eligible women, 30 were BRCA1 carriers, 7 were BRCA2 carriers, and 239 were noncarriers.
The second series of women consists of a historical cohort of BRCA1 and BRCA2 carriers affected with breast cancer. Four hundred ninety-two BRCA1/2 carriers (328 BRCA1, 152 BRCA2, and 12 BRCA1ϩBRCA2) women were ascertained as part of a North American study of the effects of various treatments of hereditary breast cancer. There were 10 participating centers. The inclusion criteria were as follows: presence of a germ-line BRCA1 or BRCA2 mutation; invasive breast cancer; diagnosed in 1975 or thereafter; at age Յ 65 years; and residents of North America at the time of diagnosis. Exclusion criteria were as follows: women with a history of breast cancer or any other cancer; before 1975; carcinoma in situ with no invasive component; tumor size Ͼ 50 mm; and evidence for locoregional or distant metastases at time of diagnosis and those with fixed mass of axillary nodes. Histological type, histological grade, and ER status were extracted from the patient charts by local collaborators. ER status was measured both biochemically and by using immunohistochemistry, but we do not have details of individuals scores because the entry sheet used allowed for three responses: positive; negative; and unknown. There were 178 BRCA1 carriers and 81 BRCA2 carriers with complete information, and these were included in the present study. In total, there were 208 BRCA1 carriers and 88 BRCA2 carriers (both study sets combined).
The third study group consisted of consecutive cases of women diagnosed with invasive breast cancer at Ͻ65 years of age at Women's College Hospital, Toronto, Ontario, Canada, from 1987 to 1997, for whom histological subtype, ER status, and histological grade were available. In all cases, ER was measured biochemically in all cases at the time of diagnosis, and a level of Ͼ10 fmol/mg protein was recorded as positive for ER. a P a/b (i.e., P 1/2 , P 1/3 , and P 2/3 , column 4) represents the P for the t test between ERϩ% in classes a and b, therefore P 1/2 is the P value for the t test comparing the ERϩ% in grade 1 and grade 2 tumors. P trend was calculated using the two-sided Cochran-Armitage trend test.
b Including all histologies (n ϭ 1131): 992 ductal and 209 nonductal cancers. The 209 nonductal cancers are distributed as follows: noncarrier, n ϭ 54 (22.6% of all noncarriers); BRCA1 carrier, n ϭ 20 (9.6%); BRCA2 carrier, n ϭ 12 (13.6%); untested, n ϭ 123, (20.6%).
were excluded, so as to match set 2 (BRCA1/2 carriers). The 596 women in this data set were not tested for BRCA1 or BRCA2 mutations. This set is referred to as the untested set in the tables.
Statistical Analysis. The percentages of ER-positive tumors were calculated by histological grade (Table 1) , by mutation status (Table 2) , and by age at diagnosis ( Table 3 ). The significance of differences was tested using the t test. The trend in percent ER positivity as histological grade increased was tested by the Cochran-Armitage test. A multiple regression model (12) was created:
This model was used to analyze how ER positivity changes with the age at diagnosis and to compare the parameters of the regression equations in each of the different mutation groups: Y represents the ER status, I j ϭ 1 if sample from mutation group j, else I j ϭ 0; j ϭ 1, 2, 3, 4 means subgroups of noncarriers, BRCA1 carriers, BRCA2 carriers, and untested individuals, respectively (Fig. 1) . As a result of regression of model (1), the four regression equations of the four groups were as follows: Y ϭ ␣ 1 ϩ ␤ 1 ageca (for group 1), and Y ϭ ␣ 1 ϩ ␣ j ϩ (␤ 1 ϩ ␤ j )ageca, for j ϭ 2, 3, 4 (for groups 2, 3, 4), respectively.
The model (1) was altered to analyze the same relationship when samples were divided by histological grade (Fig. 2) .
Pearson correlation coefficients were examined between the variables percent ER positive, histological grade, and age of diagnosis. Stepwise regression was conducted to compare the two variables (histological grade and age of diagnosis) in the prediction of ER positivity. In this case, the model was as follows: ER ϭ ␣ ϩ ␤ 1 BRϩ ␤ 2 ageca, where BR is Bloom and Richardson histological grade. All statistical analyses were done using SAS, version 8.2.
RESULTS
We studied 1131 women with breast cancer from the three study sets to determine the relationship between ER status and histological type, histological grade, age at diagnosis, and BRCA1/2 mutation status. As expected, among women with either ductal or nonductal cancers, the proportion of cancers that Fig. 1 Estrogen receptor (ER) status and age of diagnosis of breast cancer by mutation status. We regressed ER percent positive (y axis) against age at diagnosis (x axis), dividing the data by mutation status. Sample size: 239 noncarriers (group 1); 208 BRCA1 carriers (group 2); 88 BRCA2 carriers (group 3); 596 untested (group 4); total 1131. a P a/b represents the P for the t test between ERϩ% in classes a and b, therefore P 1/2 for noncarriers is the P value for the t test comparing ERϩ% in those diagnosed Ͻ45 years (class 1) and those diagnosed 45-55 years (class 2). P trend represents the P calculated from the two-sided Cochran-Armitage trend test.
are ER-positive decreases as the histological grade increases (Table 1 ). This is observed in patients with and without mutations in BRCA1/2 (Table 1) . However, for tumors of grade 2 or 3, BRCA1-related breast cancers are significantly more likely to be ER negative than are BRCA2-related noncarriers or untested individuals (all P Ͻ 0.001). There are too few grade 1 BRCA1-related cancers to observe an effect, but the trend is in the same direction. The proportion of cancers that are ER positive decreases dramatically from grade 1 to grade 3 in noncarriers: (grade 1, 90.1% ER positive and grade 3, 45.7% ER positive; P Ͻ 0.0001) and in BRCA1 carriers (71.4 and 15.7%, respectively; P ϭ 0.0024). In contrast to these groups, the difference in ER positivity between grade 1 and grade 3 tumors is not significant for BRCA2-related tumors (80.0 versus 61.0%, P ϭ 0.64), although the sample size is small (Table 1 ). There were 209 nonductal cancers (18.5% of the total). The same relationship between grade, age, and ER status is observed in nonductal cancers as in ductal cancers, but because of small numbers, statistical significance is not reached in all comparisons for nonductal cancers (data not shown).
To study the effect of mutation status on ER status independent of grade and histological type, we stratified all ductal grade 3 cancers by mutation status (Table 2) . BRCA1-related breast cancers are significantly more likely to be ER negative than tumors in BRCA2 carriers, noncarriers, or untested individuals (all P Ͻ 0.0001). Among grade 3 ductal cancers, BRCA1 tumors are 4.8 times (95% CI 2.4 -9.36) more likely to be ER negative than were tumors in noncarriers. Among BRCA1 carriers who were Ͻ45 years when they were diagnosed with a grade 3 ductal breast cancer, 87.1% (88 of 101) were ER negative. This fell to 70% (7 of 10) in women 55-65 years old at diagnosis (P ϭ 0.44). Interestingly, BRCA2 carriers with grade 2 or 3 cancers are more likely to have an ER-positive cancer than are noncarriers (80.8 versus 60.9%, P ϭ 0.0015; Tables 1 and 2 ).
For each age group (Ͻ45, 45-54, and 55-64 years), BRCA1-related breast cancers are more likely to be ER negative than cancers occurring in any other group (Table 3) . For all groups other than BRCA2 carriers, a similar increase in the percentage of tumors that were ER positive with increasing age was observed. For BRCA2-related breast cancers, there is a much smaller change in ER status with increasing age at diagnosis (3.7%, P ϭ 0.78; Table 3 ) or grade (19%, P ϭ 0.64; Table  1 ) compared with the other subtypes studied.
The relationship between age at diagnosis and percentage of ER-positive cancers was studied further by a regression analysis (model 1). The percentage of ER-positive cancers (y axis) was plotted against age at diagnosis (x axis; Fig. 1) , with the parameters. Notwithstanding the different starting points of the slopes (noncarrier versus BRCA1, P ϭ 0.0.13; noncarriers versus untested, P ϭ 0.25), BRCA1 carriers, noncarriers, and untested women have slopes that are almost parallel from ages 24 to 64.9 years (noncarrier versus BRCA1, P ϭ 0.98; noncarriers versus untested, P ϭ 0.40; Table 4 ). From Fig. 1 , it can be deduced that a 60-year-old BRCA1 carrier has the same probability of an ER-negative breast cancer as a 25-year-old noncarrier. At the youngest ages at diagnosis, the proportion of cancers that were ER positive was 0.42 (noncarriers, youngest age at diagnosis: 26.5 years), 0.06 (BRCA1 carriers, 23.9 years), 0.85 (BRCA2 carriers, 25.7 years), and 0.54 (untested individuals, 24.6 years). Despite these differences, the difference in the proportion of cancers that are ER positive between the youngest and oldest ages is almost identical in BRCA1 carriers (0.40) and noncarriers (0.41, P ϭ 0.98; Fig. 1) . The relationship between age at diagnosis and ER status in BRCA2 carriers is significantly different from that of the noncarrier group in both intercept (P ϭ 0.01) and slope (P ϭ 0.034) and that from BRCA1 carriers (P ϭ 0.0002 for intercept and P ϭ 0.041 for slope; Table 4 ). For the untested group (n ϭ 596), we also plotted absolute level of ER in fmol/mg of protein against the age at diagnosis. This resulted in a slope with an R 2 of 0.06 (data not shown). The proportion of cancers that are ER positive increases with age for all tumor grades, but the increase is most marked for grade 3 tumors (Fig. 2) in keeping with the results shown in Tables 1 and 3 . The intercept and slope for grade 3 cancers are statistically significantly different from that seen in grade 1 cancers. When comparing the intercepts and slopes between grade 2 and grade 3 cancers, the intercepts are very different, but the slopes (i.e., the change in ER status with increasing age at diagnosis) are similar (P for differences between intercepts ϭ 0.002, P for slope ϭ 0.34; Fig. 2 ). Table 5 shows in more detail the parameters estimated using model (1) . The intercept (␣) and slope (␤) for grade 3 cancers are both significantly different from the grade 1 values, whereas the parameters for grade 2 cancers are not different from grade 1 cancers. This indicates that the relationship between the ER status of a breast cancer and the age at diagnosis is dependent on the grade of the cancer, insofar as the relationship is not uniform across all grades. As the age at breast cancer diagnosis increases, the difference between the three groups becomes less noticeable. This is in contrast to the results shown in Figure 1 . Grade 1 cancers are likely to be ER positive, no matter the age at diagnosis; this is not the case for grade 3 cancers. Notably, a woman who develops a grade 3 breast cancer at 40 years of age is five times more likely to have an ER-negative cancer than a woman diagnosed Regression results: R 2 ϭ 0.180. Additional tests: P(␣ 2 ϭ ␣ 3 ) ϭ 0.0002; P(␤ 2 ϭ ␤ 3 ) ϭ 0.041; P(␣ 2 ϭ ␣ 4 ) ϭ 0.002; P(␤ 2 ϭ ␤ 4 ) ϭ 0.460; P(␣ 3 ϭ ␣ 4 ) ϭ 0.043; P(␤ 3 ϭ ␤ 4 ) ϭ 0.079.
Table 5
Parameters estimated for model (1) , as shown in Figure 2 Class Class description with a grade 1 cancer at the same age (ER percent negative ϭ 60 versus 12%).
To compare the relative importance of age and grade in the predicting of the ER status of any given tumor, stepwise regression was used. This analysis showed that both age and grade are highly predictive (␣ ϭ 0.74, P Ͻ 0.0001; ␤ 1 ϭ Ϫ2.7, P Ͻ 0.0001 for grade; and ␤ 2 ϭ 0.009, P Ͻ 0.0001 for age), but histological grade is the most important variable in predicting ER status.
DISCUSSION
To some extent, many of the clinical and pathological features of hereditary breast cancer are a reflection of the early age at diagnosis observed in most BRCA1/2 carriers. In general, young women tend to develop high-grade, ER-negative breast cancers. For example, it has been difficult to identify statistically significant differences in immunophenotypes between BRCA1 carriers and age-matched noncarriers (13) . However, detailed histological analysis, combined with immunohistochemical and expression array studies, has been successful in distinguishing BRCA1-related breast cancers from non-BRCA1-related breast cancers (14 -17) . In the general population, as women age, the likelihood of developing an ER-positive cancer increases (18, 19) . In one small study, breast cancers occurring in BRCA1 carriers older than 50 years at diagnosis were equally as likely to be ER-positive as noncarriers. This has been taken as evidence that sporadic breast cancer can develop in BRCA1 carriers (20) . Here, in a much larger study, we show that in every age interval, breast cancers that develop in BRCA1 carriers are significantly more likely to be ER negative than are breast cancers that occur in noncarriers. In particular, breast cancers occurring in older BRCA1 carriers are much more likely to be ER negative than are breast cancer developing in older noncarriers (62.0 versus 21.3%, P ϭ 0.0004; Table 3 ). Our findings suggest that ER-negative status is an intrinsic feature of BRCA1-related breast cancer. As suggested previously, it is possible that most, if not all ER-positive breast cancers occurring in BRCA1 carriers are, in fact, sporadic cancers. We could not address this question in this study, but BRCA1 sequencing or loss of heterozygosity analysis to compare the frequency of complete inactivation of BRCA1 in ER-negative and ER-positive breast cancers could help to resolve this issue. Even if this hypothesis were supported, the magnitude of the reduction in risk for contralateral breast cancer in BRCA1 carriers who received tamoxifen treatment appears to be too large to be attributable to the successful treatment of sporadic, BRCA1-unrelated breast cancers (3) .
Although this hypothesis remains a possibility, it is notable that the slope of the change in ER positivity with increasing age is almost identical for BRCA1 carriers, noncarriers, and untested individuals (Fig. 1) . This similarity in the slopes suggests that BRCA1 carriers are likely to be susceptible to the same hormonal and/or environmental factors that result in the change in ER positivity with age in the general population. The hormonal milieu of the woman at risk of breast cancer due to a BRCA1 mutation probably influences the ER status of the cancer, but the presence of the mutation sets the limits of the response in terms of the likely ER status of the breast cancer. BRCA1 carriers in the oldest age group were 2.6 times as likely as those in the youngest age group to have an ER-positive cancer (P ϭ 0.08), but this phenotype was less than half as likely to occur in older BRCA1 carriers, when compared with older noncarriers (38.0 versus 78.7%, P ϭ 0.0004; Table 3 ). The lack of change with age in the slope for BRCA2 carriers (Fig. 1) suggests that the ER status of breast cancer occurring in BRCA2 carriers is not under the same hormonal and environmental control as is nonhereditary breast cancer.
Among BRCA1 carriers, grade 3, ductal breast cancers are highly likely to be ER negative: only 21 of 138 of this type were ER positive (15.2%; Table 2 ). This suggests that in any study of breast cancer outcomes after adjuvant hormonal treatment, it is reasonable to assume that the great majority of BRCA1-related, grade 3 invasive ductal cancers are ER negative. This finding is relevant to the debate as to the potential benefit of tamoxifen for the primary prevention of BRCA1-related breast cancer. The data presented here do not suggest that ER-positive cancers predominate in any subgroup of BRCA1-related breast cancers, whether defined by age at diagnosis, grade, or histological type. Recent case-control (7) and retrospective (3) studies of contralateral breast cancer in BRCA1 and BRCA2 carriers have shown that tamoxifen is capable of reducing the incidence of second primary breast cancers by ϳ50%. The reduction was equally large in women whose first cancer was a high-grade ductal cancer as it was for other groups. Moreover, as stated above, our results suggest that the percentage of all BRCA1 carriers who develop an ER-positive breast cancer in the postmenopausal years is too small (8 of 208, or 3.9%) to account for the observed risk reductions, even if ER-positive breast cancers in BRCA1 carriers are actually sporadic breast cancers.
There are two main weaknesses in our study that may limit the interpretation of our results. Because of the diverse nature of the three study groups and the partly retrospective collection of data, we were unable to arrange central pathology review. Similarly, we were unable to determine ER status using one standardized method. Both these weaknesses mean that some of our analyses may be subject to error. However, should grade or ER measurement errors exist, they are likely to bias the results toward the null. It would be more troubling if our lack of standardization were to lead to differential misclassification. However, in group 1, all tumors were analyzed by a single pathologist without knowledge of the BRCA1/2 status, and given the era, very few of the pathologists could have been aware of the BRCA1/2-status in group 2. It is therefore implausible that there the lack of standardization has introduced a systematic bias in the measuring or reporting of either grade or ER status. It has been suggested that tumor-associated infiltrates, which are common in BRCA1-related breast cancers, may express ER (21) , and ligand-binding assays could therefore overestimate tumor ER levels. If this observation were to contribute significantly to our findings, it would mean that tumor cells in BRCA1-related cancers actually contain less ER than reported here. In this case, BRCA1-related breast cancers are even more likely to be ERnegative than we observed. Finally, we do not know the BRCA1/2 status of the untested cases (group 3). It is difficult to be sure of the expected numbers of BRCA1/2 carriers, but it is likely to be substantially Ͻ5% in most outbred populations (22) , and therefore, these hidden carriers are likely to contribute very little to the overall results obtained from the untested group.
The observation here and elsewhere (23) that BRCA1-related breast cancer is likely to be ER negative, regardless of the grade or age at diagnosis, suggests that BRCA1-related breast cancers may arise from an ER-negative breast cell. This conjecture is supported by the observation that ductal carcinoma in situ occurring in BRCA1 carriers is usually ER negative (24) . Some studies suggest that the breast stem cell is an ER-negative cell but is surrounded by ER-positive cells (25, 26) . If the regulation of ER-negative breast stem cells is partly controlled by paracrine factors released by the adjacent ER-positive cells (26) , then inhibiting estrogenic stimulation of these supporting cells either directly by estrogen deprivation, or indirectly by use of tamoxifen, could play a role in reducing the incidence of breast cancers in BRCA1 carriers.
Our observations led us to conclude that the beneficial effect of tamoxifen on both local recurrence and contralateral cancer rates in BRCA1 carriers is due to the prevention of breast cancers that arose from breast cells that either were always ER negative or those that became ER negative very soon after an initiating event. Research focused on the mechanisms by which tamoxifen reduces risk of breast cancer in BRCA1 carriers is to be encouraged.
